Predicting Non-response to Ranibizumab in Patients with Neovascular Age-related Macular Degeneration

References

• Friedman DS, O’Colmain BJ, Munoz B, et al. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol 2004;122(4):564–572
   PubMed Web of Science ®Google Scholar
• Klein R, Klein BE, Linton KL. Prevalence of age-related maculopathy. The Beaver Dam Eye Study. Ophthalmology 1992;99(6):933–943
   PubMed Web of Science ®Google Scholar
• Smith W, Assink J, Klein R, et al. Risk factors for age-related macular degeneration: pooled findings from three continents. Ophthalmology 2001;108(4):697–704
   PubMed Web of Science ®Google Scholar
• Wong TY, Chakravarthy U, Klein R, et al. The natural history and prognosis of neovascular age-related macular degeneration: a systematic review of the literature and meta-analysis. Ophthalmology 2008;115(1):116–126
   PubMed Web of Science ®Google Scholar
• Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Eng J Med 2006;355(14):1432–1444
   PubMed Web of Science ®Google Scholar
• Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Eng J Med 2006;355(14):1419–1431
   PubMed Web of Science ®Google Scholar
• Brown DM, Michels M, Kaiser PK, et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology 2009;116(1):57–65 e5
   PubMed Web of Science ®Google Scholar
• Macular Photocoagulation Study Group. Subfoveal neovascular lesions in age-related macular degeneration. Guidelines for evaluation and treatment in the macular photocoagulation study. Arch Ophthalmol 1991;109(9):1242–1257
   PubMedGoogle Scholar
• Tian J, Qin X, Fang K, et al. Association of genetic polymorphisms with response to bevacizumab for neovascular age-related macular degeneration in the Chinese population. Pharmacogenomics 2012;13(7):779–787
   PubMed Web of Science ®Google Scholar
• Yamashiro K, Tomita K, Tsujikawa A, et al. Factors associated with the response of age-related macular degeneration to intravitreal ranibizumab treatment. Am J Ophthalmol 2012;154(1):125–136
   PubMed Web of Science ®Google Scholar
• Nischler C, Oberkofler H, Ortner C, et al. Complement factor H Y402H gene polymorphism and response to intravitreal bevacizumab in exudative age-related macular degeneration. Acta Ophthalmolog 2011;89(4):e344–349
   Google Scholar
• Brantley MA Jr, Fang AM, King JM, et al. Association of complement factor H and LOC387715 genotypes with response of exudative age-related macular degeneration to intravitreal bevacizumab. Ophthalmology 2007;114(12):2168–2173
   PubMed Web of Science ®Google Scholar
• Lee AY, Raya AK, Kymes SM, et al. Pharmacogenetics of complement factor H (Y402H) and treatment of exudative age-related macular degeneration with ranibizumab. Br J Ophthalmol 2009;93(5):610–613
   PubMed Web of Science ®Google Scholar
• Kloeckener-Gruissem B, Barthelmes D, Labs S, et al. Genetic association with response to intravitreal ranibizumab in patients with neovascular AMD. Investig Ophthalmol Vis Sci 2011;52(7):4694–4702
   PubMedGoogle Scholar
• Teper SJ, Nowinska A, Pilat J, et al. Involvement of genetic factors in the response to a variable-dosing ranibizumab treatment regimen for age-related macular degeneration. Mol Vis 2010;16:2598–2604
   PubMed Web of Science ®Google Scholar
• McKibbin M, Ali M, Bansal S, et al. CFH, VEGF and HTRA1 promoter genotype may influence the response to intravitreal ranibizumab therapy for neovascular age-related macular degeneration. Br J Ophthalmol 2012;96(2):208–212
   PubMed Web of Science ®Google Scholar
• Smailhodzic D, Muether PS, Chen J, et al. Cumulative effect of risk alleles in CFH, ARMS2, and VEGFA on the response to ranibizumab treatment in age-related macular degeneration. Ophthalmology 2012;119(11):2304–2311
   PubMed Web of Science ®Google Scholar
• Boyer DS, Antoszyk AN, Awh CC, et al. Subgroup analysis of the MARINA study of ranibizumab in neovascular age-related macular degeneration. Ophthalmology 2007;114(2):246–252
   PubMed Web of Science ®Google Scholar
• Menghini M, Kurz-Levin MM, Amstutz C, et al. Response to ranibizumab therapy in neovascular AMD – an evaluation of good and bad responders. Klin Monatsblatter Augenheilkunde 2010;227(4):244–248
   PubMedGoogle Scholar
• Kaiser PK, Brown DM, Zhang K, et al. Ranibizumab for predominantly classic neovascular age-related macular degeneration: subgroup analysis of first-year ANCHOR results. Am J Ophthalmol 2007;144(6):850–857
   PubMed Web of Science ®Google Scholar
• Ying GS, Huang J, Maguire MG, et al. Baseline predictors for one-year visual outcomes with ranibizumab or bevacizumab for neovascular age-related macular degeneration. Ophthalmology 2013;120(1):122–129
   PubMed Web of Science ®Google Scholar
• Schindelin J, Arganda-Carreras I, Frise E, et al. Fiji: an open-source platform for biological-image analysis. Nature Meth 2012;9(7):676–682
   PubMed Web of Science ®Google Scholar
• Harrell FE Jr, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Statist Med 1996;15(4):361–387
   PubMed Web of Science ®Google Scholar
• Royston P, Moons KG, Altman DG, Vergouwe Y. Prognosis and prognostic research: developing a prognostic model. Br Med J 2009;338:1373-1377
   Web of Science ®Google Scholar
• Altman DG, Vergouwe Y, Royston P, Moons KG. Prognosis and prognostic research: validating a prognostic model. Br Med J 2009;338:1432--1435
   Web of Science ®Google Scholar
• Steyerberg EW, Eijkemans MJ, Harrell FE Jr, Habbema JD. Prognostic modeling with logistic regression analysis: in search of a sensible strategy in small data sets. Med Decis Making 2001;21(1):45–56
   PubMed Web of Science ®Google Scholar
• Tomany SC, Wang JJ, Van Leeuwen R, et al. Risk factors for incident age-related macular degeneration: pooled findings from 3 continents. Ophthalmology 2004;111(7):1280–1287
   PubMed Web of Science ®Google Scholar
• Klein R, Klein BE, Moss SE. Diabetes, hyperglycemia, and age-related maculopathy. The Beaver Dam Eye Study. Ophthalmology 1992;99(10):1527–1534
   PubMedGoogle Scholar
• Byun YJ, Lee SJ, Koh HJ. Predictors of response after intravitreal bevacizumab injection for neovascular age-related macular degeneration. Japan J Ophthalmol 2010;54(6):571–577
   PubMedGoogle Scholar
• Singh RP, Fu EX, Smith SD, et al. Predictive factors of visual and anatomical outcome after intravitreal bevacizumab treatment of neovascular age-related macular degeneration: an optical coherence tomography study. Br J Ophthalmol 2009;93(10):1353–1358
   PubMedGoogle Scholar